G1 Therapeutics Inc

G1 Therapeutics, Inc. (NASDAQ: GTHX) is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy.

Recent Business and Financial Updates

• Pharmacosmos Group to Acquire G1 Therapeutics
  • Enhanced Patient Access: The acquisition aims to provide patients with extensive-stage small cell lung cancer (ES-SCLC) optimal access to G1’s COSELA® (trilaciclib), a proactive multilineage myeloprotection agent.
  • Maximized Availability: Pharmacosmos’ resources and expertise in hematology and supportive care will maximize COSELA's availability for ES-SCLC patients.
  • Expanded Global Portfolio: The transaction will expand and strengthen Pharmacosmos’ global commercial portfolio.
  • Shareholder Value: G1’s shareholders will receive USD 7.15 per share in cash, totaling approximately USD 405 million in equity value.
  • Details:
    • Agreement: Pharmacosmos A/S, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., will acquire all outstanding shares of G1 Therapeutics common stock for USD 7.15 per share.
    • Premium: This represents a 68% premium to G1’s closing share price on August 6, 2024, and a 133% premium to G1’s prior 30-day volume-weighted average price.
    • Approval: The Boards of Directors of both companies have unanimously approved the transaction, expected to close late in the third quarter of 2024.
  • Strategic Fit:
    • COSELA: G1’s COSELA is the first FDA-approved product to decrease the incidence of chemotherapy-induced myelosuppression in adult patients with ES-SCLC.
    • Collaboration: The combined company will leverage Pharmacosmos’ global commercial presence and significant resources to enhance COSELA’s availability and optimize its commercial reach to oncologists.
  • G1 Therapeutics to Release Q2 2024 Financial Results and Business Update: G1 Therapeutics, Inc. (Nasdaq: GTHX) will host a webcast and conference call on August 8, 2024, at 8:30 a.m. ET to provide a financial and corporate update for the second quarter of 2024.
  • G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): G1 Therapeutics, Inc. (Nasdaq: GTHX) announced the grant of inducement stock options for 12,300 shares and 6,150 restricted stock units (RSUs) to five new employees under its Amended and Restated 2021 Inducement Equity Incentive Plan. These awards, granted as a material inducement to employment, are in accordance with Nasdaq Listing Rule 5635(c)(4).
  • G1 Therapeutics Added to the Russell 2000® and 3000® Indexes: G1 Therapeutics, Inc. (Nasdaq: GTHX) announced its inclusion in the Russell 2000® and Russell 3000® Indexes following the 2024 Russell US Indexes annual reconstitution, effective July 1, 2024. This inclusion reflects the company's ranking among the 4,000 largest U.S. stocks by market capitalization and underscores its growing prominence in the market.
  • G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Metastatic Triple Negative Breast Cancer (mTNBC): G1 Therapeutics announced that the Phase 3 PRESERVE 2 trial did not achieve statistical significance in the primary endpoint of overall survival (OS) for patients with metastatic triple negative breast cancer (mTNBC). The company will now focus on the global extensive-stage small cell lung cancer (ES-SCLC) market and is sufficiently funded to achieve anticipated profitability in the second half of 2025. Management will host a webcast and conference call today at 8:30 AM ET to discuss the results and future plans. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is August 07, 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.